New treatment option for Phantom Limb Pain
Official title Study of Phantom Limb Pain Suppression Using Neuromodulation Methods
ClinicalTrials.gov ID: NCT06644807
What this study is testing
- What it's testing
- This study assesses the effectiveness of neuromodulation in alleviating pain through the stimulation of peripheral nerves. The research involves implanting electrodes for test stimulation of peripheral nerves (PNS - Peripheral Nerve Stimulation), spinal cord (SCS - Spinal Cord Stimulation), dorsal root ganglia (DRGS - Dorsal Root Ganglion Stimulation), and motor cortex (MCS - Motor Cortex Stimulation).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Amputation of the upper limb at the level of the forearm or upper arm, or amputation of the lower limb at the level of the lower leg or thigh.
- Age between 18 and 65 years.
- Duration since amputation is at least 6 months.
- Presence of persistent chronic pain syndrome rated between 4 and 10 on the Visual Analog Scale (VAS).
- Absence of pregnancy at the time of implantation, confirmed by a pregnancy test (for female participants only).
You likely can't join if
- Presence of severe somatic pathology that hinders surgical treatment and participation in the study.
- Presence of psychiatric disorders (including a history of), severe depression, suicidal tendencies, or a history of suicide attempts.
- Presence of severe orthopedic deformity in the limb above the level of amputation.
- History of cancer.
- History of epilepsy.
- Complicated traumatic brain injury (TBI) or a history of stroke.
See the full eligibility criteria
- Amputation of the upper limb at the level of the forearm or upper arm, or amputation of the lower limb at the level of the lower leg or thigh.
- Age between 18 and 65 years.
- Duration since amputation is at least 6 months.
- Presence of persistent chronic pain syndrome rated between 4 and 10 on the Visual Analog Scale (VAS).
- Absence of pregnancy at the time of implantation, confirmed by a pregnancy test (for female participants only).
- Signed consent to participate in the study.
- Presence of severe somatic pathology that hinders surgical treatment and participation in the study.
- Presence of psychiatric disorders (including a history of), severe depression, suicidal tendencies, or a history of suicide attempts.
- Presence of severe orthopedic deformity in the limb above the level of amputation.
- History of cancer.
- History of epilepsy.
- Complicated traumatic brain injury (TBI) or a history of stroke.
- Inability to undergo electrostimulation due to other somatic pathology.
- Purulent-septic pathology.
- Drug addiction (including a history of).
- Congenital anomaly of upper limb development.
- Anomalies in the development of the central and peripheral nervous systems.
The study team makes the final eligibility decision.
Where it's taking place
- Moscow, Moscow, Russia
- Moscow, Russia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Moscow, Moscow, Russia; Moscow, Russia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.